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Strengths and limitations of this study
 ► All data and codes will be freely available after pub-
lication and study protocol was registered prior to 
completion.
 ► We assessed publication bias and study quality as 
well as subgroup analyses to attempt to explain het-
erogeneity across included studies.
 ► Study numbers were low for some subgroups mak-
ing meta- analysis challenging.
 ► Heterogeneity across extracellular vesicle sources 
was not accounted for.
ABSTRACT
Objectives Currently there is a paucity of clinically 
available regenerative therapies for stroke. Extracellular 
vesicles (EV) have been investigated for their potential as 
modulators of regeneration in the poststroke brain. This 
systematic review and meta- analysis aims to provide a 
summary of the efficacy of therapeutic EVs in preclinical 
stroke models, to inform future research in this emerging 
field.
Methods Studies were identified by a comprehensive 
literature search of two online sources and subsequent 
screening. Studies using lesion volume or neurological 
score as outcome measures were included. Standardised 
mean difference (SMD) and 95% CIs were calculated using 
a restricted maximum likelihood random effects model. 
Publication bias was assessed with Egger’s regression 
and presented as funnel plots with trim and fill analysis. 
Subgroup analysis was performed to assess the effects 
of different study variables. Study quality and risk of bias 
were assessed using the CAMARADES checklist.
Results A total of 20 publications were included in the 
systematic review, of which 19 were assessed in the 
meta- analysis (43 comparisons). Overall, EV interventions 
improved lesion volume (SMD: −1.95, 95% CI −2.72 to 
1.18) and neurological scores (SMD: −1.26, 95% CI −1.64 
to 0.87) compared with control groups. Funnel plots were 
asymmetrical suggesting publication bias, and trim and 
fill analysis predicted seven missing studies for lesion 
volume. Subgroup analysis suggested administration at 
0–23 hours after stroke was the most effective timepoint 
for EV treatment. The median score on the CAMARADES 
checklist was 7 (IQR: 5–8).
Conclusions EVs may offer a promising new avenue for 
stroke therapies, as EV- based interventions had positive 
impacts on lesion volume and neurological score in 
preclinical stroke models.
PROSPERO registration number CRD42019134925.
InTroducTIon
Stroke is a global health problem responsible 
for 6.7 million deaths annually.1 In the UK 
alone there are 1.2 million stroke survivors, a 
third of whom live with resulting disabilities, 
including impaired motor function, impaired 
speech and language communication and 
cognitive decline.2 Stroke occurs when blood 
flow to the brain becomes disrupted, leading 
to hypoxia and subsequent cell death. This 
can be caused by a blockage of blood vessels 
(ischaemic stroke) or the rupturing of vessels 
(haemorrhagic stroke). Treatments for both 
types of stroke are extremely limited. Tissue 
plasminogen activator is the only Food and 
Drug Administration- approved agent for 
ischaemic stroke but its use is limited by its 
narrow window of administration of up to 
4.5 hours from symptom onset. Thrombec-
tomy using mechanical devices is also 
approved for some ischaemic stroke cases, 
though only an estimated 10% of patients are 
eligible for this treatment.3 With no biological 
agents approved for haemorrhagic stroke, 
surgery to repair damaged blood vessels is 
the only existing treatment. Currently the 
treatments available for both stroke subtypes 
are aimed at aiding reperfusion and thus 
reducing the damage caused by stroke. This 
highlights a huge unmet need for restorative 
and regenerative therapies to alleviate func-
tional deficits and the long- term disabling 
effects of stroke.
One promising candidate for stroke 
therapy is mesenchymal stem cells (MSC). 
A recent systematic review and meta- analysis 
of 141 studies demonstrated that bone 
marrow- derived MSC transplantation leads 
to improvements in functional outcomes in 
preclinical models of cerebral ischaemia.4 
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Initially it was thought that MSCs promote repair and 
ameliorate functional deficits by differentiating into 
parenchymal cells.5 However, more recent studies have 
shown that MSCs do not engraft and differentiate in 
the stroke brain,6 but rather accumulate in the lungs 
following intravenous injection.7 Instead, the paracrine 
effects of the implanted MSCs are likely responsible for 
the restorative effects observed in previous studies. MSCs 
secrete an array of growth factors, extracellular vesicles 
(EV) and cytokines which together could mediate these 
restorative processes.
EVs are nanoscale membrane- bound vesicles which 
carry cargoes including DNA, RNA and proteins that are 
involved in intercellular signalling. EVs can be subcat-
egorised according to their biogenesis. Exosomes are 
30–100 nm in diameter and of endosomal origin while 
microvesicles (50–2000 nm) and apoptotic bodies (500–
4000 nm) are formed by outward budding of the plasma 
membrane of the cell and apoptotic cell fragments, 
respectively.8 EVs are found in biological fluids, and have 
been shown to enter the circulation, indicating that their 
effects are not limited to the cells surrounding their 
origin. At their target sites, EVs release their cargo by 
fusion with either the plasma membrane or membranes 
of the endocytic components, allowing signalling mole-
cules such as nucleic acids to alter gene expression in 
the recipient cell.9 Reported biodistribution of injected 
EVs varies between studies, and the accumulation in the 
liver, spleen and lymphatic system may be influenced 
by different routes of administration.10 Although much 
remains unknown about the biological actions of EVs, 
the field has grown rapidly in recent years, leading to the 
establishment of the International Society for Extracel-
lular Vesicles (ISEV) in 2012. Importantly, ISEV released 
a set of guidelines for researchers to adhere to when 
studying EVs, in particular to aid characterisation of EVs 
and improve reporting of functional studies.11 EVs are 
not associated with the tumorigenic and immunogenic 
caveats of cell therapies, and treatments can be prepared 
and stored in advance, making EV- based therapies an 
attractive avenue for future medical research.
Since 2013, several groups worldwide have investigated 
the potential therapeutic benefits of EVs in preclinical 
stroke models, the results of which will be analysed in 
part in this review. A major issue for the treatment of 
stroke, among other diseases, is translation; many thera-
peutic agents effective in experimental stroke have failed 
to show efficacy in human trials. Dirnagl and Macleod12 
highlight a number of reasons for this, including bias in 
preclinical studies and poor study quality. Currently there 
is no systematic review or meta- analysis examining the 
therapeutic potential of EVs in preclinical stroke models.
Aims
The aim of this review and subsequent meta- analysis is 
to examine the potential efficacy of EVs in preclinical 
stroke models, and to assess the methodological quality 
of included studies to aid future research in this field and 
improve reporting.
METhOdS
This systematic review was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses statement,13 and the protocol was preregis-
tered in the PROSPERO database.
Search strategy
PubMed and Embase (OVID) were searched according to 
the search strategy outlined in the PROSPERO protocol. 
Articles published from January 2013 were assessed by 
two independent reviewers (CJC, JMT), and the refer-
ence lists from relevant reviews were also screened for 
additional articles. The last search was performed on 16 
May 2019.
Study selection & data extraction
Full texts of relevant articles were screened for studies 
investigating the therapeutic effects of EVs in preclinical 
stroke models. Studies were included if lesion volume 
and/or neurological scores of any scale were reported as 
outcome measures. Studies in which EVs were not admin-
istered, or those without appropriate controlled groups 
were excluded. Studies were excluded if full English 
language texts were not available. Qualitative data were 
extracted for subgroup analyses and narrative synthesis. 
This included information on the study design including 
methods of EV isolation, characterisation and details 
of the intervention including route and timepoints of 
administration.
For lesion volume and neurological score, mean values 
and SEM or SD were extracted as reported in the arti-
cles. Where raw values were not given in text, the online 
graphical tool WebPlotDigitizer (https:// automeris. io/ 
WebPlotDigitizer/) was used to extract data from figures. 
Estimates were cross- checked by a second reviewer and 
any conflicts >10% difference were resolved by discus-
sion. In instances where the exact numbers of animals in 
each group were not reported and it was unclear whether 
error bars represented SEM or SD, the authors were 
emailed for clarification. If the data were not made avail-
able following two attempts to contact the authors, those 
studies were excluded from the meta- analysis.
Study quality was assessed using the CAMARADES 
(Collaborative Approach to Meta- analysis and Review 
of Animal Data in Experimental Studies) risk of bias 
checklist,14 with the following categories: (1) publica-
tion in peer- reviewed journal, (2) statement of control of 
temperature, (3) randomisation of treatment or control, 
(4) allocation concealment, (5) blinded assessment of 
outcome, (6) avoidance of anaesthetics with marked 
intrinsic properties, (7) use of animals with comorbidi-
ties, (8) sample size calculation, (9) statement of compli-
ance with regulatory requirements, and (10) statement 
regarding possible conflict of interest. Studies were 
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Figure 1 Flow diagram showing search strategy and 
inclusion and exclusion of studies for systematic review and 
meta- analysis. EV, extracellular vesicle.
recorded as positive for allocation concealment if animals 
were randomised to treatment groups after surgery or if 
blinding to surgery groups was explicitly stated. Comor-
bidities included diabetic, hypertensive or aged animals. 
Data were extracted by two independent reviewers (CJC, 
JMT) and any disagreements were resolved through 
discussion with a third author (SA).
Studies were grouped by timepoint of EV adminis-
tration with the following subgroups: administration 
before induction of stroke and up to reperfusion time; 
administration from reperfusion to 23 hours after stroke; 
24–48 hours after stroke, and multiple administrations of 
EVs across these timepoints. Routes of EV administration 
were grouped into studies delivering EVs intravenously, 
intra- arterially and other routes. Studies were classified 
as including exosome characterisation if data from the 
characterisation were included in the article. Finally, 
studies were also grouped depending on whether investi-
gators were blinded to treatment groups when measuring 
outcomes, if they included randomisation to interven-
tion groups and if researchers were blinded to surgery, 
according to the CAMARADES checklist as described 
above.
Statistical analysis
All statistical analyses were performed in RStudio 
V.1.2.1335 (RStudio, USA) using the metafor 
package (http://www. metafor- project. org/ doku. php, 
RRID:SCR_003450). Standardised mean difference 
(SMD) effect sizes were calculated using Hedges’ g. A 
random effects meta- analysis was conducted using the 
restricted maximum likelihood method for both lesion 
volume and neurological scores. Heterogeneity was 
assessed using the I2 statistic. The random effects model 
was chosen due to the high heterogeneity in the data 
set. Subgroup analyses were performed to assess the 
effects of different study variables including randomisa-
tion, blinding and timepoint of administration of effect 
size. Independent random effects models were fitted to 
subgroups, and estimates compared with a Wald- type 
test. Publication bias was assessed using funnel plots and 
confirmed with Egger’s regression. Trim and fill analysis 
was used to determine the effect size when accounting for 
unpublished studies.
RESulTS
Qualitative synthesis
A total of 491 articles were identified from our literature 
search and reference list screening (figure 1). Of these, 
20 met the inclusion criteria for our systematic review 
and study details are summarised in table 1. Most of the 
studies used ischaemic stroke models (n=18), with only 
two investigating intracerebral haemorrhage. Rats (n=15) 
and mice (n=4) were the animals most commonly studied, 
and pigs (n=1) were also used. Studies were heteroge-
neous in the functional outcome measures assessed with 
20 different behavioural tests and six neurological score 
scales used including the modified neurological severity 
score, Rogers, Belayev and Longa tests. A total of 19 
studies including 525 animals (control n=209, treatment 
n=316) were included in the meta- analysis for a total of 
43 comparisons (n=22 for lesion volume, n=21 for neuro-
logical score). One study was excluded from the meta- 
analysis as numbers of animals in experimental groups 
were not available.
The vast majority of studies (n=15) used EVs derived 
from MSCs (table 1). Other studies used macrophage- 
derived,15 neural stem cell- derived16 17 or embryonic 
stem cell- derived18 EVs. Another group isolated EVs from 
blood of animals having undergone ischaemia/reperfu-
sion injury.19 A total of 13 studies (65%) reported data on 
the characterisation of EVs (table 2). Studies also differed 
in their methods to isolate EVs, with the majority using 
ultracentrifugation (n=10) or precipitation (n=6). Other 
studies used ultrafiltration (n=2) or centrifugation at 
various speeds (n=2).
Quantitative synthesis: meta-analysis
Meta- analysis was performed on data extracted for lesion 
volume and neurological score. Overall, lesion volume was 
reduced in animals receiving EVs compared with controls 
(SMD: −1.95, 95% CI −2.72 to 1.18, figure 2). Similarly, 
neurological scores were improved in EV- treated groups 
(SMD: −1.26, 95% CI −1.64 to 0.87, figure 3). As can be 
seen from both figures, interstudy heterogeneity was 
greater for lesion volume outcome compared with neuro-
logical score (I2=79.51% and 37.77%, respectively).
Subgroup analysis was performed for lesion volume 
and neurological score (table 3). Effect sizes in lesion 
volume were significantly different (p=0.026) in studies 
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Figure 2 Effects of extracellular vesicle (EV) interventions on 
lesion volume. Forest plots of standardised mean difference 
and 95% CI. RE, random effects.
Figure 3 Effects of extracellular vesicle (EV) interventions 
on neurological score. Forest plots of standardised mean 
difference and 95% CI. RE, random effects.
that randomised animals to experimental groups (−4.36 
for studies without randomisation and −1.34 for studies 
with randomisation). For lesion volume, effect size for 
intra- arterial administration was significantly greater 
than for intravenous EV administration (−3.66 to –1.25, 
p=0.042). Administration of EVs at 0–23 hours after stroke 
appeared to be the most effective timepoint for treatment 
for both outcome measures, with effect sizes of −3.53 for 
lesion volume and −1.64 for neurological score (table 3).
Risk of bias and study quality
Risk of bias was assessed using the CAMARADES check-
list.14 The median score was 7, with an IQR of 5–8 (table 4). 
All studies analysed were published after publication of 
the Animal Research: Reporting of In Vivo Experiments 
guidelines for reporting animal experiments,20 though in 
particular the use of comorbid animals and reporting of 
sample size calculations to power studies were very low at 
5% and 15% respectively.
Publication bias was assessed and presented as funnel 
plots (figure 4). Asymmetry was confirmed for each 
outcome measure using Egger’s regression test (p<0.0001 
for lesion volume, p=0.0054 for neurological score). Trim 
and fill analysis predicted there are seven unpublished 
studies with neutral or negative impacts on lesion volume 
(figure 5) which when accounted reduced the effect size 
from −1.95 to −1.05. In contrast, no missing studies were 
estimated for neurological score data.
diSCuSSiOn
Summary of findings
This study aimed to assess the efficacy of EVs in preclin-
ical models of stroke. A total of 20 studies met the inclu-
sion criteria, with a total of 43 comparisons across 19 
studies assessed in the meta- analysis. Overall, we found 
that administration of EVs improved lesion volume and 
neurological scores. Administration of EVs from 0 to 
23 hours seemed the most effective timepoint for treat-
ment, as effect sizes were greater for both outcome meas-
ures. Study quality was assessed using the CAMARADES 
checklist,14 finding a median score of 7, though with poor 
utilisation of comorbid animals (5%) and sample size 
calculations (15%). Funnel plots were asymmetrical as 
confirmed by Egger’s regression test, suggesting there was 
publication bias. Trim and fill analysis identified there are 
seven unpublished studies reporting neutral or negative 
lesion volume data but none for neurological score.
heterogeneity in therapeutic EV studies
While most of the studies included in this review used 
MSCs for EV production, several other cell types were 
used such as neural stem cells and macrophages. The 
composition of EVs is largely dependent on the cell of 
origin and culture conditions,21 which may explain much 
of the heterogeneity in these studies. EV technology is 
still relatively new, and as such there is no ‘gold standard’ 
method for EV isolation. The 2018 ISEV guidelines22 
suggest methods should be selected based on the recovery 
and specificity required for downstream applications. The 
more common methods (ultracentrifugation and precip-
itation) are suggested to have low to intermediate speci-
ficity for EV subtypes, meaning that other non- vesicular 
components or mixed EV populations may have been 
coisolated and affected the final therapeutic EV compo-
sition. The differences in the techniques used across the 
studies included in this review are therefore another 
potential source of heterogeneity affecting outcome 
measures. Putting aside diverse EV compositions, it is also 
important to consider the treatment regimens employed 
in the included studies, in which EVs were injected via 
different routes, in different stroke models, at different 
timepoints relative to stroke onset and at different doses. 
As the pathophysiological response to stroke is highly 
dynamic and involves recruitment of different cells in the 
acute and chronic stages, it is unsurprising that the time-
point of EV administration appeared to affect the lesion 
volume and neurological scores.
issues with outcome measures
A significant issue for the stroke field is the lack of stand-
ardised testing for functional deficits. Hietamies and 
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Table 3 Subgroup meta- analysis for lesion volume and neurological score
Factor SMD (95% CI) I2 (%)
Q statistic
P value (df) Subgroup analysis P value
Lesion volume
Randomisation 0.026
  Yes (n=16) −1.34 (−1.95 to −0.725) 62.6 39.2
0.0006
15
  No (n=6) −4.36 (−6.94 to −1.77) 86.4 28.4
<0.0001
5
Blinding to stroke 0.163
  Yes (n=13) −1.59 (−2.20 to −0.97) 58.35 29.1
0.0038
12
  No (n=9) −3.31 (−5.65 to −0.97) 91.08 42.6
<0.0001
8
Blinding to outcome 0.172
  Yes (n=17) −1.65 (−2.39 to −0.91) 74 51.1
<0.0001
16
  No (n=5) −3.93 (−7.11 to −0.75) 90.7 21.6
0.0002
4
EV characterisation 0.412
  Yes (n=15) −1.60 (−2.30 to −0.90) 60 39.9
0.0003
14
  No (n=7) −2.39 (−4.14 to −0.64) 89.2 32.9
<0.0001
6
Timepoint of administration Prior vs 0–23 hours: 0.761
Prior vs 23–48 hours: 0.666
  Pretreatment (n=3) −2.74 (−6.72 to 1.24) 94.7 11.7
0.0029
2 Prior vs multiple: 0.509
  0–23 hours (n=5) −3.53 (−6.64 to −0.411) 86.7 25.3
<0.0001
4 0–23 hours vs 23–48 hours: 
0.324
  23–48 hours (n=7) −1.82 (−3.16 to −0.478) 80.7 23.4
0.0007
6 0–23 hours vs multiple: 0.188
  Multiple (n=7) −1.39 (−2.05 to −0.720) 34.3 11.5
0.0747
6 23–48 hours vs multiple: 0.569
Route of administration
  Intravenous (n=17) −1.25 (−1.83 to −0.670) 58.1 43.8
0.0002
16 Intravenous vs intra- arterial: 
0.042
  Intra- arterial (n=3) −3.66 (−5.91 to −1.41) 68.2 6.77
0.0339
2 Intravenous vs other: 0.239
  Other (n=2) −4.58 (−10.1 to 0.937) 82.3 5.64
0.0176
1 Intra- arterial vs other: 0.762
Neurological score
Randomisation 0.12
  Yes (n=15) −1.07 (−1.52 to −0.622) 36.6 24.2
0.0433
14
  No (n=6) −1.64 (−2.20 to −1.08) 0 10.2
0.0705
5
Blinding to stroke 0.902
  Yes (n=10) −1.28 (−1.68 to −0.874) 4.51 11.1
0.270
9
  No (n=11) −1.22 (−1.98 to −0.465) 64.2 26.3
0.0034
10
Blinding to outcome 0.224
  Yes (n=18) −1.12 (−1.49 to −0.747) 25.7 26.0
0.0744
17
Continued
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Factor SMD (95% CI) I2 (%)
Q statistic
P value (df) Subgroup analysis P value
  No (n=3) −2.54 (−4.80 to −0.277) 83.8 8.30
0.0157
2
EV characterisation 0.49
  Yes (n=16) −1.20 (−1.69 to −0.708) 50 32.3
0.0059
15
  No (n=5) −1.48 (−2.09 to −0.866) 0 4.35
0.361
4
Timepoint of administration
  Pretreatment (n=0) N/A N/A N/A N/A 0–23 hours vs 23–48 hours: 
0.715
  0–23 hours (n=4) −1.64 (−3.87 to 0.60) 86.7 15.6
0.0014
3 0–23 hours vs multiple: 0.765
  23–48 hours (n=13) −1.21 (−1.63 to −0.796) 20.1 17.6
0.128
12 23–48 hours vs multiple: 0.894
  Multiple (n=4) −1.27 (−2.08 to −0.466) 31.7 4.46
0.212
3
Route of administration
  Intravenous (n=15) −1.10 (−1.55 to −0.650) 42.3 28.9
0.0107
14 Intravenous vs intra- arterial: 
0.208
  Intra- arterial (n=5) −1.74 (−2.63 to −0.854) 30.6 5.88
0.209
4 Intravenous vs other: 0.353
  Other (n=1) −1.71 (−2.90 to −0.516) N/A N/A N/A Intra- arterial vs other: 0.961
EV, extracellular vesicle; N/A, not applicable (for subgroups with fewer than two members where comparisons could not be made); SMD, 
standardised mean difference.
Table 3 Continued
Table 4 Study quality as assessed by CAMARADES risk of 
bias checklist14
% of included 
studies
(1) Publication in peer- reviewed journal 100
(2) Statement of control of temperature 75
(3) Randomisation of treatment or control 60
(4) Allocation concealment 45
(5) Blinded assessment of outcome 75
(6) Avoidance of anaesthetic with marked 
intrinsic properties
90
(7) Use of comorbid animals 5
(8) Sample size calculation 15
(9) Statement of compliance with regulatory 
requirements
100
(10) Statement regarding possible conflict 
of interest
90
Median study quality (IQR) 7 (5–8)
Figure 4 Publication bias assessed by funnel plots for 
lesion volume (A) and neurological score (B). White funnel 
area denotes 95% CIs for publication bias.
colleagues23 identified 74 functional outcome meas-
ures reported across 636 preclinical stroke studies, the 
majority of which were neurological deficit scores of 
varying scales. Although useful to compare data across 
multiple studies, the differing scales and criteria used to 
detect deficits can confound studies. Furthermore, due 
to the nature of scoring, neurological deficit scores are 
subjective and can give false positive scores.24 Rodents 
show spontaneous recovery in weeks following stroke 
onset, which may render neurological scores ineffec-
tive at later timepoints due to their insensitivity to more 
complex deficits.24 Other behavioural tests that may be 
more appropriate for detecting long- term functional 
deficits include staircase test catwalk analysis.24 25 Finally, 
Menezes et al26 suggest that lesion volume may be less 
relevant than lesion location and topology with regard to 
stroke severity, which raises the question of whether lesion 
volume alone should be used as an outcome measure for 
preclinical stroke studies.
limitations
It is important to note that data were extracted from 
the final timepoints of each study in order to observe 
the longer term effects of the EV treatments. However, 
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Figure 5 Trim and fill analysis of lesion volume showing 
published (filled circles) and unpublished (empty circles) 
studies.
studies were not conducted for the same number of days 
after stroke onset, with the shortest sacrificing animals at 
24 hours, and the longest at 60 days. As mentioned above, 
spontaneous recovery occurs after stroke onset, and thus 
effect sizes for neurological scores may be confounded 
by the timepoints; the shortest study by Zheng et al15 had 
the third highest calculated effect size, though longer 
studies may have had larger effect sizes, had the data been 
extracted from more acute timepoints.
Our study was limited by the articles included; several 
studies did not measure either lesion volume or neuro-
logical score. This is unsurprising given the number of 
functional outcome measures characterised, though it 
means potentially relevant data regarding EV efficacy 
in preclinical stroke models were not included in this 
review. The decision to use these outcome measures was 
made based on the number of studies employing these 
measures, to capture the maximum number of relevant 
studies that could be easily compared.
While extracting study design data, we noticed substantial 
heterogeneity across the included studies, with regard to 
timepoint and routes of EV administration. For this reason, 
we assigned studies to subgroups we believed may be rele-
vant to the reported outcomes. However, due to the paucity 
of studies, some subgroups were small and dispropor-
tionate, meaning that subgroup analysis is unlikely to have 
been sufficiently powered. Indeed, only one comparison for 
randomisation for lesion volume was statistically significant. 
We did not account for heterogeneity arising from usage of 
EVs from different sources and with various modifications, 
as the EVs and their contents have not been fully character-
ised, making subgroups challenging to define.
COnCluSiOnS
Overall, EV- based interventions had positive impacts 
on lesion volume and neurological score in preclinical 
stroke models, indicating that EVs may hold great poten-
tial for future translational stroke research. Subgroup 
analyses may have been confounded by considerable 
heterogeneity in study design and the low number of 
included studies. However, given their efficacy across 
studies with notably different treatment regimens, 
the positive effects of EVs may be wide ranging in the 
contexts of neuroprotection, repair and regeneration. 
To fully unlock the potential of EVs as therapy for stroke, 
it is important to determine the mechanisms by which 
they elicit their effects, perhaps investigating the roles 
of specific cargo contained in the EVs. Translation of 
preclinical EV research into a clinical setting will likely 
require methodological standardisation and improve-
ments in EV characterisation in order to meet regulatory 
requirements for human therapy. Interest in therapeutic 
EVs is expanding, with study numbers increasing yearly, 
therefore we expect that a clearer understanding of the 
most effective EVs and treatment regimens may soon 
come to light.
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